| Proposed Ticker: ALNX | 3550 General Atomics Court | |
| Exchange: NASDAQ-National Market | San Diego, California 92121 | |
| Industry: Service | (619) 455-3200 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 8/9/96 | |
| U.S. Shares Filed: | 2,500,000 | Filing Range: | $10.00 - $12.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $27,500,000 | |
| Primary Shares: | 2,500,000 | Expenses: | - | |
| Secondary Shares: | 0 | Shs Out After: | ||
| Manager | Tier | Phone |
| PaineWebber Incorporated | Lead Manager | (212) 713-2626 |
| Needham & Company | Co-manager | (212) 371-8300 |
| Sutro & Company Inc. | Co-manager | (415) 445-8323 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 6/30/96 | 6/30/95 | 6/30/96 | ||
| Revenue: | $3.77 | $4.22 | $1.60 | Assets: | $7.75 |
| Net Income: | -$0.76 | $1.36 | -$0.27 | Liabilities: | $6.43 |
| EPS: | -$0.17 | $0.30 | -$0.06 | Equity: | $1.31 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a drug discovery company that is applying its highly integrated and comprehensive approach to rapidly and cost-effectively discover and optimize novel, small molecule drug candidates. The company's proprietary core drug discovery technology, Pharmacophore Directed Parallel Synthesis, accelerates the steps necessary to discover small molecule drug candidates, from the initial identification of compounds that exhibit activity at selected biological targets to the progression of these compounds to drug candidates for human clinical trials. PDPS combines combinatorial chemistry with computational and medicinal chemistries which, when used in conjunction with high throughout screening and pharmacology, forms an integrated drug discovery platform that can be broadly applied to a wide array of biological targets. An important element of the company's strategy is to enter into collaborations with pharmaceutical companies. The company has collaboration agreements with Astra Pharma, Inc., Nordisk A/S and Roche Bioscience, a division of Syntex Inc., a wholly owned subsidiary of Roche Holding Ltd. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research and development, facilities expansion and working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.